Cizzle Biotechnology to take early lung cancer test to £3b China market (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss a full commercial development and royalty agreement to develop and market Cizzle Biotechnologies early lung cancer diagnostic tests in China.

Allan provides us with more information around the deal, tells us about the diagnostic technology and what it does, explains who its partners are in China and how this arrangement in China will work from a financial point of view and potentially generate future revenues for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology completes evaluation programme with Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat

    Cizzle Biotech

    Cizzle Biotechnology AGM to be held on 27 June 2022

    Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, have been sent to